Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Role of bone morphogenetic protein-9 in the regulation of glucose and lipid metabolism

(2019) Min Yang et al.   FASEB JOURNAL

The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis

(2019) Zobair M. Younossi et al.   JOURNAL OF HEPATOLOGY

Elevated leptin and decreased adiponectin independently predict the post-thrombotic syndrome in obese and non-obese patients

(2018) Sandra Mrozinska et al.   Scientific Reports

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies

(2018) Norbert Stefan et al.   Lancet Diabetes & Endocrinology

BMP-9 interferes with liver regeneration and promotes liver fibrosis

(2017) Katja Breitkopf-Heinlein et al.   GUT

Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes

(2017) Alessandro Mantovani et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Circulating bone morphogenetic protein-9 in relation to metabolic syndrome and insulin resistance

(2017) Xiaohui Xu et al.   Scientific Reports

BMP-9 enhances fibroblast growth factor 21 expression and suppresses obesity

(2016) Sooho Kim et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Decreased circulating BMP-9 levels in patients with Type 2 diabetes is a signature of insulin resistance

(2016) Yong Luo et al.   CLINICAL SCIENCE

New risk-scoring system including non-alcoholic fatty liver disease for predicting incident type 2 diabetes in East China: Shanghai Baosteel Cohort

(2015) Guang-Yu Chen et al.   Journal of Diabetes Investigation

Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study

(2011) R. M. Williamson et al.   DIABETES CARE

Identification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver

(2009) Manu V. Chakravarthy et al.   CELL

Modulation of Bone Morphogenetic Protein-9 Expression and Processing by Insulin, Glucose, and Glucocorticoids: Possible Candidate for Hepatic Insulin-Sensitizing Substance

(2008) Luciana Chagas Caperuto et al.   ENDOCRINOLOGY